Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
286 Leser
Artikel bewerten:
(1)

Vitestro launches new website and first public video of Aletta Autonomous Robotic Phlebotomy Device

UTRECHT, The Netherlands, Jan. 12, 2026 /PRNewswire/ -- Vitestro, a pioneer in medical robotics advancing automated diagnostic blood collection, today announced the launch of its new corporate website and the release of its first publicly available video. The video demonstrates the Aletta Autonomous Robotic Phlebotomy Device (ARPD) performing a diagnostic blood draw. Together, these milestones represent an important step in Vitestro's evolution toward broader education, clearer communication, and deeper engagement across the healthcare ecosystem. This reflects the company's continued effort to establish autonomous robotic phlebotomy as a new standard for safe, reliable, and efficient diagnostic blood collection.

The new website provides a comprehensive overview of Vitestro and Aletta, including the technology, intended diagnostic use, and role in modern clinical laboratory and outpatient care settings. It also serves as the primary platform for Vitestro's newly released public video, which walks viewers through the Aletta blood draw experience from both patient and clinical workflow perspectives, reinforcing how Aletta fits into existing care delivery models.

The Aletta ARPD is designed to autonomously perform diagnostic blood collection. The system combines multimodal imaging, advanced robotics, and artificial intelligence to identify suitable veins, guide needle insertion, and collect blood samples with high precision and consistency. Aletta is intended to support phlebotomy departments by performing routine diagnostic blood draws, helping address staffing challenges, reduce human-dependent variability, standardize quality, enhance the overall patient experience, and enable greater operational predictability and scalability in high volume clinical environments.

The newly released video explains how Aletta works by visually demonstrating each phase of the process, from arm positioning at the device through completion of the blood draw. It provides a clear, practical view of how autonomous blood collection is delivered in routine clinical practice, marking the first time Vitestro has publicly shared a detailed visual explanation of the technology and its clinical workflow.

"Our new website and public video reflect a deliberate step toward more open communication and education," said Toon Overbeeke, Chief Executive Officer of Vitestro. "As we bring autonomous robotic phlebotomy into routine clinical practice, it is essential that healthcare professionals and patients clearly understand how the technology works and how it integrates into real world care delivery. By making our technology and clinical workflow more visible, we are enabling informed adoption, building confidence, and supporting the responsible establishment of a new standard for diagnostic blood collection."

The Aletta video is available to watch on the new Vitestro website. For more information, visit www.vitestro.com.

About Vitestro
Vitestro is a global leader in medical robotics advancing diagnostic blood collection through autonomous technology. Headquartered in the Netherlands, the company brings deep expertise in engineering, robotics, artificial intelligence, and commercialization. Vitestro has developed Aletta, the world's first and only CE marked Autonomous Robotic Phlebotomy Device (ARPD), establishing a new category and benchmark for diagnostic blood collection. By integrating advanced robotics, multimodal imaging, and AI, Vitestro is enabling greater precision, operational efficiency, and an improved patient experience in clinical settings. Aletta is currently CE marked and is available for clinical use in Europe. Aletta is not cleared or approved by the U.S. Food and Drug Administration (FDA) and is not available for commercial or clinical use in the United States. Vitestro is actively pursuing U.S. regulatory authorization alongside broader global expansion, with the goal of advancing autonomous diagnostic blood collection globally.

Cision View original content:https://www.prnewswire.co.uk/news-releases/vitestro-launches-new-website-and-first-public-video-of-aletta-autonomous-robotic-phlebotomy-device-302657323.html

© 2026 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.